6:05 PM
 | 
Oct 07, 2008
 |  BC Extra  |  Company News

Lilly TB initiative in-licenses compounds

The Lilly TB Drug Discovery Initiative received an exclusive license from Summit (LSE:SUMM) to a series of undisclosed, preclinical compounds to treat tuberculosis (TB) in developing countries. The...

Read the full 117 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >